Posters

Analysis of corneal densitometry 3 months after accelerated corneal collagen cross-linking

Poster Details

First Author: M. Böhm GERMANY

Co Author(s):    M. Remy   M. Shajari   T. Kohnen              

Abstract Details

Purpose:

To analyse changes in corneal densitometry 3 months after accerlerated corneal collagen crosslinking (CXL) in patients suffering from progressive keratoconus, pellucid marginal degeneration (PMD) or iatrogenic ectasia (IE) after corneal refractive surgery.

Setting:

Department of Ophthalmology, University of Frankfurt, Germany

Methods:

This study retrospectively reviewed charts and anterior segment data of patients who had undergone accelerated pulsed (1 second “on”, 1 second “off”) epithelium-off CXL (0.1% VibeX RapidTM Riboflavine; 30 mW/cm2 for 4 minutes; 7.2 J/cm2; 8 minutes total radiation time) for treatment of progressive keratoconus, PMD or IE after corneal refractive surgery. Visual acuity, clinical, topographic, pachymetric and densitometric data were extracted from charts, Scheimpflug-tomography (Pentacam HR, Oculus) and Optical Coherence Tomography (VisanteTM OCT, Zeiss). Data from before surgery and at follow-up 3 months after treatment was statistically analyzed.

Results:

The study evaluated 20 eyes of 20 patients. The mean densitometry of different stromal corneal layers (anterior, middle, posterior) and in four zones (0-2 mm, 2-6 mm, 6-10 mm, 10-12 mm) of the entire cornea depth increased compared to baseline. The anterior (120 μm) stromal layer within the 0-2 mm zone showed a significant elevation after three month (p< 0.006). A mean stromal demarcation line was apparent at a depth of 203.00 μm +/-12.51 (SD). There was no change in mean best corrected distance visual acuity, however, a decrease in pachymetry (μm) was found after three months.

Conclusions:

Accelerated CXL results in an increase in densitometry, particularly in the anterior stromal layer of the cornea within the 0-2 mm zone compared to baseline at three months postoperatively. Further research, including a longer follow up time, is needed to verify these findings.

Financial Disclosure:

One or more of the authors travel has been funded, fully or partially, by a competing company